A Phase 3 interventional study of Recombinant Hepatitis B new Bulk vaccine and DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine in Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction and Pertussis Vaccine Adverse Reaction, sponsored by PT Bio Farma. Withdrawn at 3 sites in Indonesia. Open to participants aged 1 Day to 3 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by PT Bio Farma · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This bridging study is a randomized, double-blind, two arms parallel group, prospective intervention study. The primary objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma).
This bridging study is a randomized, double blind, two arms parallel groups, prospective intervention study. Total 220 infants, 0-3 days old will be involved in this study. The subject will be divided into 2 groups, 110 subjects are the investigational group and 110 subjects are the active comparator group.
The objective of this study is to evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma) and to asses the safety of DTP-HB-Hib Vaccine (Bio Farma) and Recombinant Hepatitis B Vaccine using new Hepatitis B bulk (Bio Farma).
1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.
Browse Hepatitis B studies →PT Bio Farma is the lead sponsor of 47 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose Recombinant Hepatitis B new Bulk vaccine at birth + 3 doses Pentavalent with Recombinant HepB new Bulk vaccine
Biological: Recombinant Hepatitis B new Bulk vaccine · Biological: DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
1 dose Recombinant Hepatitis B vaccine (Registered) + 3 doses Pentabio with Recombinant HepB new Bulk vaccine
Biological: Recombinant Hepatitis B vaccine (Registered BioFarma) · Biological: Pentabio
1 dose of Recombinant Hepatitis B vaccine using new Hepatitis B bulk (Bio Farma) 1 dose of 0.5 ml Recombinant Hepatitis B new Bulk vaccine dose of DTP-HB-Hib using new Hepatitis B Bulk vaccine injected intramuscularly into the left external antero-lateral thigh region.
3 doses of DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine
1 dose of Recombinant Hepatitis B vaccine (Registered Bio Farma)
3 doses of Pentabio
To evaluate protectivity of DTP-HB-Hib Vaccine (Bio Farma) using new Hepatitis B bulk (Bio Farma)
Percentage of infants with anti-diphtheria titer and anti-tetanus titer more than 0.01 IU/ml, anti HbsAg titer more than 10 mIU/ml, and anti PRP-TT titer more than 0.15 microgram/ml 28 days after the last injection of DTP-HB-Hib using new Hepatitis B bulk (Bio Farma) vaccine group.
Time frame: 28 days
To asses the local and systemic reactions within 30 minutes
Local reaction and systemic events occurring within 30 minutes after immunization.
Time frame: 30 minutes
To asses the local and systemic reactions within 30 minutes to 7 days after immunization
Local reaction and systemic events occurring after 30 minutes to 7 days after immunization.
Time frame: 7 days
To asses the local and systemic reactions within 7 days to 28 days after immunization
Local reaction and systemic events occurring after 7 days to 28 days following the vaccination.
Time frame: 28 days
To asses the serious adverse event
Any serious adverse event occuring from inclusion until 28 days after the last dose
Time frame: 28 days
Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.